GlassScriptPhysician profile
Ramanjeet Singh
NPI 1922196328
$5,408.81
in general payments reported to CMS, 2019-2025
30 companies · $2,178 in 2025
The $2,178 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $310 · 2021: $152 · 2022: $778 · 2023: $475 · 2024: $1,138 · 2025: $2,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945 · Travel and Lodging: $1,838 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.37 |
| Travel and Lodging | $1,837.73 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,787.47 | 2025 | Indigo System |
| Intuitive Surgical, INC. | $896.55 | 2022-2024 | |
| Abbott Laboratories | $352.93 | 2019-2025 | 2nd Gen Centrimag Primary Console |
| Janssen Pharmaceuticals, INC | $340.53 | 2019-2024 | Xarelto |
| Noah Medical Corporation | $278.07 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.90 | 2019-2025 | Jardiance, Jascayd, Ofev |
| E.R. Squibb & Sons, L.L.C. | $232.06 | 2019-2024 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $146.61 | 2019-2024 | Andexxa, Lokelma |
| Insmed, INC. | $145.06 | 2022 | |
| Merck Sharp & Dohme LLC | $109.74 | 2019-2024 | Zerbaxa |
| Medtronic Vascular, INC. | $106.98 | 2020 | |
| Novo Nordisk INC | $85.68 | 2025 | Ozempic |
| Abiomed | $69.31 | 2023 | Impella |
| Ucb, INC. | $68.52 | 2021-2022 | |
| Pfizer INC. | $67.62 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $67.12 | 2024-2025 | Cresemba |
| Boston Scientific Corporation | $63.54 | 2024-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $54.25 | 2019-2022 | |
| Inari Medical, INC. | $48.95 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Vifor Pharma, INC. | $40.56 | 2019 | |
| Nabriva Therapeutics, Plc | $36.52 | 2020 | |
| Ceribell, INC. | $33.75 | 2024 | Pocket Eeg Device |
| Actelion Pharmaceuticals US, INC. | $27.57 | 2025 | Opsynvi |
| La Jolla Pharmaceutical Company | $21.39 | 2023 | Giapreza |
| Philips North America LLC | $17.60 | 2020 | |
| Smith+Nephew, INC. | $13.98 | 2020 | |
| Gilead Sciences, INC. | $13.81 | 2021 | |
| Scpharmaceuticals INC. | $13.17 | 2023 | |
| Xeris Pharmaceuticals, INC. | $12.24 | 2022 | |
| Paratek Pharmaceuticals, INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramanjeet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.